Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell
transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the …

The immune reactivity of allogeneic lymphocytes plays a major role in the control of
leukemia after bone marrow transplantation. In patients with recurrent leukemia after marrow …

Allogeneic stem cell transplantation (SCT) offers the only hope for cure for many adults with
acute leukemia. Unfortunately, many patients relapse and die of their disease even after …

In allogeneic bone marrow transplantation (allo-BMT), donor lymphocytes play a central
therapeutic role in both graft-versus-leukemia (GvL) and immune reconstitution. However …

Background Lymphoma associated with Epstein-Barr virus (EBV) is a complication of bone
marrow transplantation that responds poorly to standard forms of therapy. The lymphoma is …

Allogeneic bone marrow transplantation (BMT) is the only effective treatment for hematologic
malignancies resistant to conventional chemotherapy. Until recently, no cure existed for …

Cytotoxic T lymphocytes (CTL) specific for human minor histocompatibility (H) antigens can
be isolated from the blood of major histocompatibility complex (MHC)-matched allogeneic …

We studied 346 patients after bone marrow transplantation (BMT) for chronic myeloid
leukemia (CML) for the presence of the bcr-abl transcript detected by the polymerase chain …

The efficacy and toxicity of donor leukocyte infusions (DLI) after unrelated donor bone
marrow transplantation (BMT) is largely unknown. We identified 58 recipients of unrelated …

We retrospectively analyzed outcomes among 307 consecutive patients who had recurrent
or persistent acute leukemia (n= 244), chronic myelogenous leukemia in blast phase (CML; …